Zydus Group pioneers breakthrough with anti-diabetic drug Lipaglyn

05 Jun 2013 Evaluate

Zydus Group has pioneered a breakthrough with anti-diabetic drug Lipaglyn, a novel drug targeted at bridging an unmet healthcare need for treating Diabetic Dyslipidemia or Hypertriglyceridemia in Type II diabetes, not controlled by statins alone. The drug has been approved for launch in India by the Drug Controller General of India (DCGI).

With a novel action that oilers lipid and glucose lowering effects in one molecule, Lipaglyn is the first Glitazar to be approved anywhere in the world.

Cadila Healthcare, the flagship company of Zydus Cadila Group, focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

Zydus Lifesciences Share Price

884.80 8.70 (0.99%)
22-Jan-2026 13:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1618.80
Dr. Reddys Lab 1222.15
Cipla 1375.80
Zydus Lifesciences 884.80
Lupin 2171.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×